Last reviewed · How we verify

Mycophenolic Acid Oral Product

Simon Tremblay, PharmD, PhD · FDA-approved active Small molecule

Mycophenolic Acid Oral Product is a Immunosuppressant; IMPDH inhibitor Small molecule drug developed by Simon Tremblay, PharmD, PhD. It is currently FDA-approved for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients. Also known as: Myfortic, MPA.

Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune disease.

Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses. Used for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.

At a glance

Generic nameMycophenolic Acid Oral Product
Also known asMyfortic, MPA
SponsorSimon Tremblay, PharmD, PhD
Drug classImmunosuppressant; IMPDH inhibitor
TargetInosine monophosphate dehydrogenase (IMPDH) type II
ModalitySmall molecule
Therapeutic areaImmunology; Transplantation
PhaseFDA-approved

Mechanism of action

Mycophenolic acid is a non-competitive, selective inhibitor of IMPDH type II, the enzyme responsible for guanosine nucleotide synthesis in lymphocytes. By depleting guanosine nucleotides, it preferentially inhibits T and B cell proliferation while sparing other cell types, resulting in immunosuppression. This mechanism makes it effective for preventing allograft rejection and treating autoimmune conditions.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Mycophenolic Acid Oral Product

What is Mycophenolic Acid Oral Product?

Mycophenolic Acid Oral Product is a Immunosuppressant; IMPDH inhibitor drug developed by Simon Tremblay, PharmD, PhD, indicated for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients.

How does Mycophenolic Acid Oral Product work?

Mycophenolic acid inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune disease.

What is Mycophenolic Acid Oral Product used for?

Mycophenolic Acid Oral Product is indicated for Prevention of organ rejection in renal transplant recipients, Prevention of organ rejection in cardiac transplant recipients, Prevention of organ rejection in hepatic transplant recipients, Lupus nephritis.

Who makes Mycophenolic Acid Oral Product?

Mycophenolic Acid Oral Product is developed and marketed by Simon Tremblay, PharmD, PhD (see full Simon Tremblay, PharmD, PhD pipeline at /company/simon-tremblay-pharmd-phd).

Is Mycophenolic Acid Oral Product also known as anything else?

Mycophenolic Acid Oral Product is also known as Myfortic, MPA.

What drug class is Mycophenolic Acid Oral Product in?

Mycophenolic Acid Oral Product belongs to the Immunosuppressant; IMPDH inhibitor class. See all Immunosuppressant; IMPDH inhibitor drugs at /class/immunosuppressant-impdh-inhibitor.

What development phase is Mycophenolic Acid Oral Product in?

Mycophenolic Acid Oral Product is FDA-approved (marketed).

What are the side effects of Mycophenolic Acid Oral Product?

Common side effects of Mycophenolic Acid Oral Product include Diarrhea, Leukopenia, Anemia, Infection, Nausea, Vomiting.

What does Mycophenolic Acid Oral Product target?

Mycophenolic Acid Oral Product targets Inosine monophosphate dehydrogenase (IMPDH) type II and is a Immunosuppressant; IMPDH inhibitor.

Related